


Protein Sciences
CORPORATION

**Influenza Summit
May 14, 2015
Atlanta GA**



The Company: Protein Sciences *Manufacturing Vaccines for Over 30 Years*


Only American owned and based
influenza company

Meriden, CT
(FDA licensed)



Pearl River, NY
(FDA licensed)







Flublok

- First recombinant influenza vaccine
- Manufacturing platform allows us to match wild type influenza strain rather than an egg adapted strain
- Can produce vaccine in one month should a strain change be needed


Wayne: W
third bullet
comment
from Mary






Flublok

- Licensed for those 18 years and older
- Trivalent
- Three times more antigen than standard dose
- No preservatives, egg products, gelatin, antibiotics, or formaldehyde
- Shelf life 6 months




Projected Availability

- Available August/September 2015
- Production up to 1.5 M doses depending on demand
- Distributors: FFF, McKesson, Cardinal Health; Henry Schein



In Development


- **Quadrivalent formulation**
 - Expected 2016-17 season
- **Pediatric Approval**
 - Expected 2017-18 season
- **Extended Shelf Life**
 - Data supporting 1 year shelf life ready for submission
- **Room Temperature Stable Product**
 - Modification of non-immunogenic portion of HA antigen permits storage at temperatures over 90°F for over 6 months






There if you need us

Recombinant pandemic influenza vaccines are projected to be available much sooner than those produced with egg-based technology.



Adapted from R. Robinson's presentation to FDA's VRBPAC on February 29, 2012



Summary

- Flublok
 - Is an FDA approved influenza vaccine approved for individuals 18 years of age and above
 - Is the only vaccine that is egg, gelatin, mercury, antibiotic, and formaldehyde free
 - Is the only vaccine recommended by the ACIP for egg allergic individuals
 - Is the only vaccine that matches the wild type virus
 - Has three times the active ingredient
 - Clinical trials suggest greater seroprotection in individuals over 65
 - Is the only vaccine platform capable of providing early protection against emerging pandemic strains